Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (SUPN) filed a Current Report on Form 8-K dated January 28, 2026. The report discloses the entry into a material definitive agreement regarding a prior merger transaction.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a contractual amendment rather than a financial performance report.
Material Changes
On January 22, 2026, the Company entered into a First Amendment to the Agreement and Plan of Merger originally dated September 12, 2018, with Reich Consulting Group, Inc. acting as the Securityholder Representative. The Amendment specifically addresses:
- The timing of certain milestone payments.
- The payment terms for said milestones under the Merger Agreement.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard incorporation by reference of the full Amendment text (Exhibit 10.1). Certain portions of the Amendment were omitted from the public filing as confidential information under Regulation S-K.
Investor Verification Checklist
- Review Exhibit 10.1 (First Amendment to Agreement and Plan of Merger) for specific details on the revised milestone payment schedule.
- Verify the identity of the Securityholder Representative (Reich Consulting Group, Inc.) and their role in the amended agreement.
- Confirm the status of the original Merger Agreement dated September 12, 2018, to understand the context of the amendment.
- Note that specific financial impacts of the amendment are not quantified in this 8-K summary.